02 May 2003
PARP and myocardial ischaemia-reperfusion injury
C. ThiemermannMed Sci Monit 2003; 9(1): 70-0 :: ID: 15213
Abstract
There is now good evidence that inhibitors of PARP activity reduce the tissue injury caused by regional myocardial ischemia and reperfusion. For instance, various, chemically distinct inhibitors of PARP activity [including 3-aminobenzamide (3-AB) and 1, 5-dihydroxyisoquinoline (ISO)] reduce the infarct size caused by ischaemia-reperfusion injury of the rabbit heart in vivo. In addition, 3-AB and ISO also reduce the infarct size caused by regional myocardial ischaemia and reperfusion in the heart of the rat in vivo and in vitro. Moreover, ISO reduces the contractile dysfunction, the fall in high-energy phosphates caused by global myocardial ischemia and reperfusion in the rat heart. Exposure of human cardiac myoblasts in vitro results in an increase in PARP activity, and secondary cell death. Inhibition of this increase in PARP activity reduces the impairment in mitochondrial respiration as well as the associated cell death caused by these reactive oxygen species. The tissue injury caused by coronary artery occlusion and reperfusion in PARP-1 knock out mice is substantially reduced (when compared to their wild-type litter mates). Potent, water-soluble inhibitors of PARP activity (including 5-aminoisoquinolinone, PJ-34 and others) cause a substantial reduction in myocardial infarct size in the rat in vivo. Taken together, these findings support the view that (1) the excessive activation of PARP contributes to myocardial reperfusion injury, and (2) potent, water-soluble inhibitors of PARP activity may be useful in conditions associated with acute myocardial ischemia and reperfusion. These conditions may include acute myocardial infarction, coronary angioplasty, cardiac transplantation and bypass heart surgery. References: 1.Thiemermann C et al: Proc Natl Acad Sci USA, 1997; 94: 679-683
Keywords: Heart, Infarction, 5-AIQ, cardiac ischemia, ischaemia
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
21 Mar 2024 : Meta-Analysis
Economic Evaluation of COVID-19 Screening Tests and Surveillance Strategies in Low-Income, Middle-Income, a...Med Sci Monit In Press; DOI: 10.12659/MSM.943863
10 Apr 2024 : Clinical Research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Dep...Med Sci Monit In Press; DOI: 10.12659/MSM.942612
06 Mar 2024 : Clinical Research
Enhanced Surgical Outcomes of Popliteal Cyst Excision: A Retrospective Study Comparing Arthroscopic Debride...Med Sci Monit In Press; DOI: 10.12659/MSM.941102
06 Mar 2024 : Clinical Research
Prevalence and Variation of Medical Comorbidities in Oral Surgery Patients: A Retrospective Study at Jazan ...Med Sci Monit In Press; DOI: 10.12659/MSM.943884
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952